4.7 Article

Fragmentation of Care in Patients with Peritoneal Metastases Undergoing Cytoreductive Surgery

期刊

ANNALS OF SURGICAL ONCOLOGY
卷 -, 期 -, 页码 -

出版社

SPRINGER
DOI: 10.1245/s10434-023-14318-1

关键词

Cytoreductive surgery; HIPEC; Colorectal neoplasms; Appendiceal neoplasms; Chemotherapy

向作者/读者索取更多资源

This study aimed to explore whether fragmenting surgical and systemic therapeutic care between different institutions affects the outcomes of patients undergoing cytoreductive surgery (CRS) for peritoneal metastases. The results showed that patients undergoing CRS at a high-volume center may safely receive systemic therapy at outside-network facilities with comparable survival rates and rates of serious adverse events.
BackgroundThe delivery of multimodal treatment at a high-volume center is known to optimize the outcomes of gastrointestinal malignancies. However, patients undergoing cytoreductive surgery (CRS) for peritoneal metastases often must 'fragment' their surgical and systemic therapeutic care between different institutions. We hypothesized that this adversely affects outcomes.Patients and MethodsAdults undergoing CRS for colorectal or appendiceal adenocarcinoma at our institution between 2016 and 2022 were identified retrospectively and grouped by care network: 'coordinated care' patients received exclusively in-network systemic therapy, while 'fragmented care' patients received some systemic therapy from outside-network providers. Factors associated with fragmented care were also ascertained. Overall survival (OS) from CRS and systemic therapy-related serious adverse events (SAEs) were compared across the groups.ResultsAmong 85 (80%) patients, 47 (55%) had colorectal primaries and 51 (60%) received fragmented care. Greater travel distance [OR 1.01 (CI 1.00-1.02), p = 0.02] and educational status [OR 1.04 (CI 1.01-1.07), p = 0.01] were associated with receiving fragmented care. OS was comparable between patients who received fragmented and coordinated care in the colorectal [32.5 months versus 40.8 months, HR 0.95 (CI 0.43-2.10), p = 0.89] and appendiceal [31.0 months versus 27.4 months, HR 1.17 (CI 0.37-3.74), p = 0.55] subgroups. The frequency of SAEs (7.8% versus 17.6%, p = 0.19) was also similar.ConclusionsThere were no significant differences in survival or SAEs based on the networks of systemic therapy delivery. This suggests that patients undergoing CRS at a high-volume center may safely receive systemic therapy at outside-network facilities with comparable outcomes.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据